Protease formulation for treatment of microbial infections

1 . A composition comprising:

i. 0.02 to 0.09% w/w trypsin;

ii. 50 to 62% w/w glycerol;

iii. 0.002 to 0.04% w/w hyaluronic acid; and

iv. 0.01 to 0.2% w/w salt comprising a divalent calcium ion.

2 . The composition according to claim 1 , wherein the composition further comprises:

a. 0.1 to 0.4% w/w buffer;

b. a monosaccharide or a monosaccharide derivative;

c. collagen; and/or

d. water.

3 . The composition according to claim 1 , wherein the composition comprises or consists essentially of:

i. 0.02 to 0.09% w/w trypsin;

ii. 50 to 62% w/w glycerol;

iii. 0.002 to 0.04% w/w hyaluronic acid;

iv. 0.01 to 0.1% w/w calcium dichloride;

v. 0.1 to 0.4% w/w Tris or MOPS;

vi. 0.0 to 0.2% w/w mannose; and

vii. 0.0 to 0.3% w/w collagen.

4 . The composition according to claim 1 , wherein the composition comprises or consists essentially of:

i. 0.04% w/w trypsin;

ii. 60% w/w glycerol;

iii. 0.02 to 0.04% w/w hyaluronic acid;

iv. 0.01% w/w calcium dichloride; and

v. 0.1% w/w Tris or MOPS.

5 . The composition according to claim 1 , wherein a pH of the composition is between 6.0 to 7.5.

6 . The composition according to claim 1 , wherein the composition is in the form of a spray, a gel, a cream, lotion, an ointment, a foam, or a dental chew.

7 . A method of treating a condition in a subject, wherein said condition is selected from the group consisting of microbial infections, dermatological conditions and oral conditions, said method comprising administering the composition according to claim 1 to said subject.

8 . The method according to claim 7 , wherein:

a. the microbial infection is selected from the group consisting of bacterial infections, fungal infections, yeast infections and viral infections,

b. the dermatological condition is a skin infection or an inflammatory skin disease, or

c. the oral condition is an oral infection or a dental infection.

9 . The method according to claim 8 , wherein the inflammatory skin disease is selected from the group consisting of atopic dermatitis, psoriasis, rosacea and acne.

10 . The method according to claim 7 , wherein the subject is a mammal.

11 . The method according to claim 10 , wherein the mammal is a dog, cat, horse or a human.

12 . The method according to claim 7 , wherein the composition is in the form of a spray, a gel, a cream, lotion, an ointment, a foam, or a dental chew.

13 . The method according to claim 7 , wherein the administration is topical administration.

14 . A method for prevention and/or reduction of biofilm formation, wherein the method comprises administration of a composition according to claim 1 .

15 . The method according to claim 14 , wherein the biofilm is a biofilm in or on a mammal.

16 . The method according to claim 15 , wherein the mammal is a dog, cat, horse or a human.

17 . The method according to claim 14 , wherein the biofilm is a biofilm of a biological surface.

18 . The composition according to claim 1 , wherein the composition consists of:

i. 0.02 to 0.09% w/w trypsin;

ii. 50 to 62% w/w glycerol;

iii. 0.002 to 0.04% w/w hyaluronic acid;

iv. 0.01 to 0.2% w/w calcium dichloride;

v. 0.1 to 0.4% w/w buffer; and

vi. water.

19 . The composition according to claim 1 , wherein the composition consists of:

i. 0.04 to 0.09% w/w trypsin;

ii. 50 to 62% w/w glycerol;

iii. 0.002 to 0.02% w/w hyaluronic acid;

iv. 0.01% w/w calcium dichloride;

v. 0.1 to 0.4% w/w buffer; and

vi. water.

20 . The composition according to claim 1 , wherein the composition consists of:

i. 0.04% w/w trypsin;

ii. 60% w/w glycerol;

iii. 0.002 to 0.02% w/w hyaluronic acid;

iv. 0.01% w/w calcium dichloride;

v. 0.1% w/w buffer; and

vi. water.